



How electrical dyssynchrony worsens Heart Failure

Anggia Chairuddin Lubis




20 min




SA node

Dyssynchrony?



Modified from DOI [10.3389/fcvm.2022.843969](https://doi.org/10.3389/fcvm.2022.843969)




Ezekowitz, JA et al. Canadian Heart Failure Guidelines 2017


Table 1 Pathophysiological mechanisms of cardiomyopathies associated with arrhythmias or electrical disturbances

	Tachy-cardiomyopathy	PVC-mediated cardiomyopathy	AF-mediated cardiomyopathy	LBBB-mediated cardiomyopathy
Triggers				
Rhythm	Fast but regular	Irregular	Irregular	Regular
Post-extrasystolic potentiation	Absent	Present ^a	Variable	Absent
AV coupling	Preserved ^b	Dissociated ^{c,d}	Non-existent	Preserved ^e
LV dyssynchrony	Only present in VT	Intermittent ^{c,f}	None	Continuous
Myocardial blood flow	Reduced ^f	??	Likely reduced	reduced (septum)
Haemodynamic compromise	Present, low EF	(?) Likely present	(?) Likely present	Present, low EF
Intrinsic autonomic nerve activity	(?) Unchanged	Significantly increased ^f	g	g
Cardiac intrinsic effects				
Tissue				
Inflammation	Present ^a	Absent	g	g
Fibrosis	Increased ^a	Mild ^f	g	Variable
Oxidative, metabolic stress	Present	(?) Likely present	(?) Likely present	Present
Cellular				
Ventricular electrical remodelling	Present	Present ^f	g	Present
Ca ²⁺ transient	Reduced ^f	Reduced ^f	g	Reduced ^f
Action potential duration	Increased ^f	Prolonged ^f (heterogeneous)	g	Heterogeneous ^f
β-adrenergic signalling	Decreased ^f	g	g	Decreased
Organ				
Hypertrophy	Eccentric ^a	Eccentric ^f	g	Asymmetric, eccentric
Ejection fraction	Reduced ^a	Reduced ^a	Reduced ^d	Reduced ^a
Extrinsic (non-cardiac) effects				
Neurohumoral	+; BNP; Symp; RAAS	+; BNP; Symp; RAAS	+; BNP; Symp; RAAS	+; BNP; Symp; RAAS
Recovery				
LV ejection fraction	Normalized ^a	Normalized ^a	Normalized ^d	Normalized ^a
Dimensions	Partially dilated ^a	Normalized ^a	g	Normalized ^d
Diastolic dysfunction	Persistent ^d	g	g	g
Electrical remodelling	g	g	g	Partial reversal
Hypertrophy	Reactive ^a	g	g	Partial reversal
Fibrosis	Reactive/persistent ^a	(?) Persistent ^f	g	g



Dyssynchrony by mechanism






Prinzen F, et al. European Heart Journal 2022;43:1917-1927

Dys-synchronopathy

CENTRAL ILLUSTRATION Abnormal Conduction-Induced Cardiomyopathy: Causes, Triggers, and Therapy and Prevention



Huizar JF, et al. J Am Coll Cardiol. 2023;81(12):1192-1200.


Huizar JF, et al. J Am Coll Cardiol. 2023;81(12):1192-1200.

TABLE 1 Summary of Conduction Abnormality-Induced CM

	RVP-CM	LBBB-CM	Pre-Excitation-CM
Incidence	Unknown	17%-38% after 4 y of LBBB diagnosis ^{5,29}	Unknown
Prevalence	12%-20% after 1-15 y ²⁰⁻²³	2%-20% in patients with CM and LBBB referred for CRT (4-11 y) ^{30,31,42}	65% in patients with pre-excitation and LV dysfunction ³⁷
Risk factors/predictors	Time with high RVP (mo-y) RVP burden >40% (min 20%) ^{22,23,27} Older age ²⁷ Intrinsic QRS duration ²⁰ Paced QRS duration (>160 ms) ^{21,26,27} Prior LV systolic dysfunction ²⁰ LV dyssynchrony ^{12,22} Global longitudinal strain ²⁸ Male sex ^{3,20} Higher myocardial scar ²⁷	Time from LBBB diagnosis >4 y Older population	Right-sided and septal AP ^{36,37} Younger population (children) ^{35,37} Must rule out incessant or recurrent tachycardia
Treatment	CRT (LBBAP preferred over BiV or His pacing)	CRT (LBBAP preferred over BiV or His pacing)	Radiofrequency ablation ^{36,37} Antiarrhythmic (flecainide) ⁴⁷
Predictors of recovery	Shortening QRS duration, ^a QRS duration >150 ms, body mass index <30 kg/m ² , LA volume, female ³⁹	LV diastolic diameter and mild LV systolic dysfunction (>42%) ^{37,39} Shortening QRS duration, ^a QRS duration >150 ms, body mass index <30 kg/m ² , LA volume, female ³⁹	Age <6 y ³⁷
Outcomes	Improves LV function, NYHA functional class, and probably outcomes (no data)	Improves LVEF, NYHA functional class Decrease mortality and HF admissions	Improves LV function and dimensions ³⁷ ; unknown outcomes (no data)

^aData derived from overall super-responder cardiac resynchronization therapy (CRT) data likely representing right ventricular pacing (RVP)-cardiomyopathy (CM) and left bundle branch block (LBBB).

BiV = biventricular pacing; HB = His bundle; LBBAP = left bundle branch area pacing; LV = left ventricular; NYHA = New York Heart Association.



Pacing Induced Cardiomyopathy

LVEF <50%


$\Delta EF >10\%$

HF hospitalisation


New onset AF

Ponnusamy SS, et al. Heart 2023;0:1–9

CRT: patient selection



CRT: pacing sites




- 1+2 conventional epicardial CRT
- 1+3 endocardial CRT
- 1+4 wireless endocardial CRT
- 5 His bundle pacing
- 6 LBB pacing
- 7 LV septal pacing

Prinzen F, et al. European Heart Journal 2022;43:1917-1927

Tachy-myopathy Irregulopathy AV un-coupling

CENTRAL ILLUSTRATION Arrhythmia-Induced Cardiomyopathies: Possible Triggers, Mediators, Effect, and Recovery


	Tachycardia	Frequent PVCs	Atrial Fibrillation
Triggers	Increased HR	<ul style="list-style-type: none"> • LV dyssynchrony • AV dissociation • HR irregularity • Intermittent tachycardia • Sympathetic dysregulation • Post-extrasystolic potentiation 	<ul style="list-style-type: none"> • HR irregularity • Sympathetic dysregulation • Loss of atrial contraction
Mediators	<ul style="list-style-type: none"> • Ca^{2+} overload • Ca^{2+} mishandling 	<ul style="list-style-type: none"> • Ca^{2+} overload • Ca^{2+} mishandling ??? 	<ul style="list-style-type: none"> • Ca^{2+} mishandling ???
Effect	<ul style="list-style-type: none"> • Fibrosis • Myocyte and electrical remodeling • Contractile dysfunction • Neurohormonal activation 	<ul style="list-style-type: none"> • Myocyte and electrical remodeling • Contractile dysfunction ? Fibrosis 	<ul style="list-style-type: none"> • Contractile dysfunction ???
Arrhythmia Suppression	<p>Ablation</p>	<p>Antiarrhythmic drugs</p>	
Recovery	<ul style="list-style-type: none"> • Normalized LVEF • Ventricular dilatation • Diastolic dysfunction • Reactive hypertrophy • Persistent fibrosis 	<ul style="list-style-type: none"> • Normalized LVEF and dimensions 	<ul style="list-style-type: none"> • Normalized LVEF ???




Huizar, J.F. et al. J Am Coll Cardiol. 2019;73(18):2328-44.

LVEF progression significantly affected by PVC burden

FIGURE 3 Linear Decrease of LV Ejection Fraction With Sequential Increase in PVC Burden in an Experimental Model



Huizar, J.F. et al. J Am Coll Cardiol. 2019;73(18):2328-44.



Prinzen F, et al. European Heart Journal 2022;43:1917-1927

	CM resulting in PVCs	PVCs causing CM
Patient characteristics	Older with known heart disease	Healthy otherwise
Comorbidities	CAD, myocarditis, RV dysplasia ^a	No prior cardiac hx
Echocardiogram	Segmental hypokinesis, LVEF <25%	Global hypokinesis, LVEF 35 ± 10% ^b
Cardiac MRI (late gadolinium enhancement)	Significant scar	Absence or minimal scar burden (≤ 9 g)
PVC frequency	<5000/24 h (<5%)	$\geq 10\,000/24$ h ($\geq 10\%$)
PVC pattern	Multifocal	Monomorphic
QRS morphology	Non-specific	RVOT/LVOT/ epicardial
Response to PVC suppression	No change in LV function	Improvement of LV function


Management Strategies

Know your enemy..

TABLE 2 Reversible and Irreversible Causes of Cardiomyopathy

Reversible	Irreversible
Transient ischemia/post-cardiac arrest	Extensive/multiple myocardial infarctions
Subacute valvular heart disease	Hypertrophic cardiomyopathy
Uncontrolled hypertension	Cardiac sarcoidosis
LBBB - cardiomyopathy	End-stage valvular heart disease
Pacing-induced cardiomyopathy	Infectious (e.g., Chagas disease)
Drug or alcohol abuse	
Endocrine (severe hypothyroidism)	
PVC-induced cardiomyopathy	
Stress-induced cardiomyopathy	
Peripartum cardiomyopathy	
Inflammatory/infectious (e.g., myocarditis, sepsis)	

Huizar, J.F. et al. J Am Coll Cardiol. 2019;73(18):2328-44.




Prinzen F, et al. European Heart Journal 2022;43:1917-1927


Catheter Ablation for Atrial Fibrillation with Heart Failure


Nassir F. Marrouche, M.D., Johannes Brachmann, M.D., Dietrich Andresen, M.D., Jürgen Siebels, M.D.,
Lucas Boersma, M.D., Luc Jordaeans, M.D., Béla Merkely, M.D., Evgeny Pokushalov, M.D.,
Prashanthan Sanders, M.D., Jochen Proff, B.S., Heribert Schunkert, M.D., Hildegard Christ, M.D.,
Jürgen Vogt, M.D., and Dietmar Bänsch, M.D., for the CASTLE-AF Investigators*

Death or Hospitalization for Worsening Heart Failure



His Bundle Pacing vs Biventricular Pacing Following Atrioventricular Node Ablation in Patients with Atrial Fibrillation and Reduced Ejection Fraction: A Multicenter, Randomized, Crossover Study. The ALTERNATIVE-AF trial.





Case

Male, 71yo



HFrEF

LVEF 35%

Persistent AF, rate poorly controlled w/ BB and digoxin

Intolerant to ACEi / ARB

NT-pro-BNP 8305



→ |
% → 50%

Conclusion

Irregulopathy

- Prevent
- Detect: AF, RV pacing, PVC/VT, AT
- Know your enemy: reversible?

Tachymyopathy

- Management:
 - Pharmacological
 - Catheter ablation
 - Device re-synchronization

AV-uncoupling




Dyssynchronopathy

Prinzen F, et al. European Heart Journal 2022;43:1917-1927



TERIMA KASIH

Waktu	Symposium 4A	Peran
Sabtu, 24 Juni 2023 14.20-14.40	Topic 1 : How electrical dissynchrony worsens heart failure conditions	Pembicara : Anggia Chairuddin Lubis, MD



Kirk and Kass. *Circ Res*. 2013;113:765-776





Figure 2 Pathogenesis of pacing induced cardiomyopathy. AO, aorta; LA, left atrium; LV, left ventricle.

FOMUSAMSY 33, Et al. Viert 2023;0:1-9

Key messages

- ⇒ Pacing induced cardiomyopathy (PIC) is the terminology coined to describe the chronic RV pacing related left ventricular (LV) dysfunction, the incidence of which increases with the duration of RV pacing.
- ⇒ Most acceptable definition for PIC would be an LV ejection fraction (LVEF) of <50%, absolute decline of LVEF by ≥10% and/or new-onset heart failure (HF) symptoms after pacemaker implantation.
- ⇒ It will be clinically relevant to expand the definition of PIC beyond LV ejection fraction and to include HF hospitalisation due to systolic or diastolic dysfunction and new-onset atrial fibrillation (AF).
- ⇒ Male sex, advanced age, high RV pacing burden, coronary artery disease, pre-existing AF, baseline prolonged QRS duration, baseline low LVEF and prolonged paced QRS duration are the risk factors for the development of PIC.
- ⇒ Periodic assessment of patients with RV pacing is essential as nearly a fifth of them can develop PIC. A comprehensive device clinic programme may help in early diagnosis and better management of patients with PIC.
- ⇒ Cardiac resynchronisation therapy using biventricular pacing is the most commonly used approach for the management of PIC.
- ⇒ Conduction system pacing is a promising alternative both for prevention and treatment of PIC as it provides physiological activation of the ventricles and avoids dyssynchrony.

Ponnusamy SS, et al. Heart 2023;0:1–9



Ponnusamy SS, et al. Heart 2023;0:1–9